All Stories

  1. Selective Uptake of Macromolecules to the Brain in Microfluidics and Animal Models Using the HAVN1 Peptide as a Blood-Brain Barrier Modulator
  2. Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery
  3. M. tuberculosis Transcription Machinery: A Review on the Mycobacterial RNA Polymerase and Drug Discovery Efforts
  4. Spermidine/Spermine N1-Acetyltransferase 1 (SAT1)—A Potential Gene Target for Selective Sensitization of Glioblastoma Cells Using an Ionizable Lipid Nanoparticle to Deliver siRNA
  5. Structural Design and Synthesis of Novel Cyclic Peptide Inhibitors Targeting Mycobacterium tuberculosis Transcription
  6. Immune Modulation by Antigenic Peptides and Antigenic Peptide Conjugates for Treatment of Multiple Sclerosis
  7. Enhancing Intestinal Absorption of a Model Macromolecule via the Paracellular Pathway using E-Cadherin Peptides
  8. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles
  9. Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice
  10. Noninvasive Brain Delivery and Efficacy of BDNF to Stimulate Neuroregeneration and Suppression of Disease Relapse in EAE Mice
  11. Improving In Vivo Brain Delivery of Monoclonal Antibody Using Novel Cyclic Peptides
  12. In Vivo Brain Delivery and Brain Deposition of Proteins with Various Sizes
  13. Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors
  14. Orf239342 from the mushroom Agaricus bisporus is a mannose binding protein
  15. Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model
  16. Protein PEGylation for cancer therapy: bench to bedside
  17. Conjugates of Cell Adhesion Peptides
  18. Enhancing In Vivo Brain Delivery of Peptide and Protein Molecules in Animal Models
  19. Drug Delivery
  20. Physiological, Biochemical, and Chemical Barriers to Oral Drug Delivery
  21. Meet Our Regional Editor:
  22. Prodrug strategies for brain delivery
  23. Modulation of Intercellular Junctions by Cyclic-ADT Peptides as a Method to Reversibly Increase Blood–Brain Barrier Permeability
  24. Routes of Administration and Dose Optimization of Soluble Antigen Arrays in Mice with Experimental Autoimmune Encephalomyelitis
  25. Co-Delivery of Autoantigen and B7 Pathway Modulators Suppresses Experimental Autoimmune Encephalomyelitis
  26. Pathways and progress in improving drug delivery through the intestinal mucosa and blood–brain barriers
  27. Structure, Size, and Solubility of Antigen Arrays Determines Efficacy in Experimental Autoimmune Encephalomyelitis
  28. Modulation of Blood–Brain Barrier Permeability in Mice Using Synthetic E-Cadherin Peptide
  29. 1H, 13C and 15N backbone assignment of the EC-1 domain of human E-cadherin
  30. Hyaluronic Acid Graft Polymers Displaying Peptide Antigen Modulate Dendritic Cell Response in Vitro
  31. Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis
  32. Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor
  33. Single-step grafting of aminooxy-peptides to hyaluronan: A simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis
  34. Biodegradable Nanoparticles Surface Modification Techniques With cIBR Peptide Targeting to LFA-1 Expressing Leukemic Cells
  35. Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis
  36. Vaccinelike and Prophylactic Treatments of EAE with Novel I-Domain Antigen Conjugates (IDAC): Targeting Multiple Antigenic Peptides to APC
  37. Peptide Delivery
  38. Chemical Pathways of Peptide and Protein Degradation
  39. Methotrexate (MTX)–cIBR Conjugate for Targeting MTX to Leukocytes: Conjugate Stability and In Vivo Efficacy in Suppressing Rheumatoid Arthritis
  40. Immune modulating peptides for the treatment and suppression of multiple sclerosis
  41. Improving the stability of the EC1 domain of E-cadherin by thiol alkylation of the cysteine residue
  42. Vaccine-like Controlled-Release Delivery of an Immunomodulating Peptide To Treat Experimental Autoimmune Encephalomyelitis
  43. I-Domain-Antigen Conjugate (IDAC) for Delivering Antigenic Peptides to APC: Synthesis, Characterization, and in Vivo EAE Suppression
  44. Suppression of EAE and prevention of blood–brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor
  45. Peptides and Proteins for Treatment and Suppression of Type 1 Diabetes
  46. Rapid Identification of Fluorochrome Modification Sites in Proteins by LC ESI-Q-TOF Mass Spectrometry
  47. Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics
  48. Calcium Condensed LABL-TAT Complexes Effectively Target Gene Delivery to ICAM-1 Expressing Cells
  49. Antigen-specific blocking of CD4-Specific immunological synapse formation using BPI and current therapies for autoimmune diseases
  50. Nanoparticles Targeting Dendritic Cell Surface Molecules Effectively Block T Cell Conjugation and Shift Response
  51. Controlling Ligand Surface Density Optimizes Nanoparticle Binding to ICAM-1
  52. Enhancement of Drug Absorption through the Blood−Brain Barrier and Inhibition of Intercellular Tight Junction Resealing by E-Cadherin Peptides
  53. MODULASI JUNCTION ANTAR SEL MENGGUNAKAN PEPTIDA KADHERIN UPAYA MENINGKATKAN PENGHANTARAN OBAT
  54. Peptide-mediated targeted drug delivery
  55. ChemInform Abstract: Oxazolophanes as Masked Cyclopeptide Alkaloid Equivalents: Cyclic Peptide Chemistry without Peptide Couplings.
  56. ChemInform Abstract: Delocalized Carbanions in Synthesis
  57. LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
  58. A Peptide from the Beta-strand Region of CD2 Protein that Inhibits Cell Adhesion and Suppresses Arthritis in a Mouse Model
  59. ChemInform Abstract: Synthesis of an Esterase-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymic Stability Using a 3-(2′-Hydroxy-4′,6′-dimethylphenyl)-3,3-Dimethylpropionic Acid Promoiety
  60. ChemInform Abstract: Synthesis of an Esterase-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability Using an Acyloxyalkoxy Promoiety
  61. ChemInform Abstract: Steric Hindrance is a Key Factor in the Coupling Reaction of (Acyloxy) Alkyl-α-halides with Phenols to Make a New Promoiety for Prodrugs.
  62. ChemInform Abstract: Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a Therapeutic Approach to Inflammation and Autoimmune Diseases
  63. cIBR Effectively Targets Nanoparticles to LFA-1 on Acute Lymphoblastic T Cells
  64. Immune response to controlled release of immunomodulating peptides in a murine experimental autoimmune encephalomyelitis (EAE) model
  65. Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor: Structure Optimization and Pharmacokinetics
  66. The Role of Thiols and Disulfides on Protein Stability
  67. The Role of Covalent Dimerization on the Physical and Chemical Stability of the EC1 Domain of Human E-Cadherin
  68. Solution structure of a novel T-cell adhesion inhibitor derived from the fragment of ICAM-1 receptor: Cyclo(1,8)-Cys-Pro-Arg-Gly-Gly-Ser-Val-Cys
  69. Adhesion of pancreatic beta cells to biopolymer films
  70. Characterization of Multiple Stable Conformers of the EC5 Domain of E-cadherin and the Interaction of EC5 with E-cadherin Peptides
  71. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells
  72. Effect of Modification of the Physicochemical Properties of ICAM-1-Derived Peptides on Internalization and Intracellular Distribution in the Human Leukemic Cell Line HL-60
  73. The aqueous conformation of cyclo(1,6)Ac-Cys-Arg-Gly-Asp-Phe-Pen-NH2
  74. Conformational analysis of cyclo(2,9)-Ac-QCRSVEGSCG-OH from the C-terminal loop of human growth hormone
  75. Inhibition of homotypic adhesion of T-cells: secondary structure of an ICAM-1-derived cyclic peptide
  76. Evaluation of the physical stability of the EC5 domain of E-cadherin: Effects of pH, temperature, ionic strength, and disulfide bonds
  77. Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor
  78. Structural Modifications of ICAM-1 Cyclic Peptides to Improve the Activity to Inhibit Heterotypic Adhesion of T cells
  79. PLGA Nanoparticle−Peptide Conjugate Effectively Targets Intercellular Cell-Adhesion Molecule-1
  80. Mechanism of Internalization of an ICAM-1-Derived Peptide by Human Leukemic Cell Line HL-60: Influence of Physicochemical Properties on Targeted Drug Delivery
  81. ICAM-1 Peptide Inhibitors of T-cell Adhesion bind to the allosteric site of LFA-1. An NMR Characterization
  82. ICAM-1 Peptide Inhibitors of T-cell Adhesion bind to the allosteric site of LFA-1. An NMR Characterization
  83. Sequence Recognition of ?-LFA-1-derived Peptides by ICAM-1 Cell Receptors: Inhibitors of T-cell Adhesion
  84. Suppression of Type 1 Diabetes in NOD Mice by Bifunctional Peptide Inhibitor: Modulation of the Immunological Synapse Formation
  85. Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor
  86. Cell Adhesion Molecules for Targeted Drug Delivery
  87. Synthesis and chemical stability of a disulfide bond in a model cyclic pentapeptide: Cyclo(1,4)‐Cys‐Gly‐Phe‐Cys‐Gly‐OH
  88. Cell Adhesion Molecules for Targeted Drug Delivery
  89. Structure and Function of the Intercellular Junctions: Barrier of Paracellular Drug Delivery
  90. Characterization of Binding Properties of ICAM-1 Peptides to LFA-1: Inhibitors of T-cell Adhesion
  91. Effects of Amino Acid Chirality and the Chemical Linker on the Cell Permeation Characteristics of Cyclic Prodrugs of Opioid Peptides
  92. Deamidation of model β-turn cyclic peptides in the solid state
  93. Modulation of Cell Adhesion Molecules in Various Epithelial Cell Lines after Treatment with PP2 †
  94. Physiological, Biochemical, and Chemical Barriers to Oral Drug Delivery
  95. Drug Delivery
  96. Effects of An E-cadherin-Derived Peptide on the Gene Expression of Caco-2 Cells
  97. Design, structure and biological activity of β-turn peptides of CD2 protein for inhibition of T-cell adhesion
  98. Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides
  99. Reductive Alkylation of Lipase: Experimental and Molecular Modeling Approaches
  100. Expression, purification, and structural study of the EC4 domain of E-cadherin
  101. Solution structure of a peptide derived from the β subunit of LFA-1
  102. Syntheses of cyclic prodrugs of RGD peptidomimetics with various macrocyclic ring sizes: evaluation of physicochemical, transport and antithrombic properties
  103. Synthesis and comparison of physicochemical, transport, and antithrombic properties of a cyclic prodrug and the parent RGD peptidomimetic
  104. A Peptide Derived from LFA-1 Protein that Modulates T-cell Adhesion Binds to Soluble ICAM-1 Protein
  105. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors
  106. Synthesis and stability study of a modified phenylpropionic acid linker-based esterase-sensitive prodrug
  107. Localized production of human E-cadherin-derived first repeat in Escherichia coli
  108. Synthesis of a novel cyclic prodrug of RGD peptidomimetic to improve its cell membrane permeation
  109. Structural and ICAM-1-Docking Properties of a Cyclic Peptide from the I-domain of LFA-1: An inhibitor of ICAM-1/LFA-1-mediated T-cell adhesion
  110. Molecular Dynamics Simulations of Conformational Behavior of Linear RGD Peptidomimetics and Cyclic Prodrugs in Aqueous and Octane Solutions
  111. Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion
  112. Modeling alternative binding registers of a minimal immunogenic peptide on two class II major histocompatibility complex (MHC II) molecules predicts polarized T-cell receptor (TCR) contact positions
  113. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases
  114. Synthesis of Cyclic Prodrugs of Aggrastat and Its Analogue with a Modified Phenylpropionic Acid Linker
  115. Steric hindrance is a key factor in the coupling reaction of (acyloxy) alkyl-α-halides with phenols to make a new promoiety for prodrugs
  116. Synergistic inhibitory activity of α- and β-LFA-1 peptides on LFA-1/ICAM-1 interaction
  117. Rapid Determination of Substrate Specificity of Clostridium histolyticum  -Collagenase Using an Immobilized Peptide Library
  118. Regulation of Cadherin-Cadherin Interaction: Secondary Structure of the HAV and ADT Peptides Derived from Human E-Cadherin Sequence
  119. Utilization of ICAM-1 Peptide Conjugates for Drug Targeting to T-Cells
  120. Conjugation with L-Glutamate forin vivoBrain Drug Delivery
  121. Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function
  122. Effect of Conformation on the Rate of Deamidation of Vancomycin in Aqueous Solutions
  123. Enhancement of Transport of D-Melphalan Analogue by Conjugation with L-Glutamate across Bovine Brain Microvessel Endothelial Cell Monolayers
  124. Comparison of the Solution Conformations of a Cell-Adhesive Peptide LBE and its Reverse Sequence EBL
  125. PEPTIDES DERIVED FROM ICAM-1 AND LFA-1 MODULATE T CELL ADHESION AND IMMUNE FUNCTION IN A MIXED LYMPHOCYTE CULTURE1
  126. Effect of conformation on the conversion of cyclo-(1,7)-Gly-Arg-Gly-Asp-Ser-Pro-Asp-Gly-OH to its cyclic imide degradation product
  127. Solution stability of linear vs. cyclic RGD peptides
  128. The effect of conformation on the solution stability of linear vs. cyclic RGD peptides
  129. Binding and internalization of an ICAM‐1 peptide by the surface receptors of T cells
  130. The effect of conformation on the membrane permeation of coumarinic acid‐ and phenylpropionic acid‐based cyclic prodrugs of opioid peptides
  131. The effect of conformation of the acyloxyalkoxy‐based cyclic prodrugs of opioid peptides on their membrane permeability
  132. Structural recognition of an ICAM‐1 peptide by its receptor on the surface of T cells: conformational studies of cyclo (1, 12)‐Pen‐Pro‐Arg‐Gly‐Gly‐Ser‐Val‐Leu‐Val‐Thr‐Gly‐Cys‐OH
  133. Synthesis and evaluation of the physicochemical properties of esterase‐sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers
  134. Synthesis and evaluation of the physicochemical properties of esterase‐sensitive cyclic prodrugs of opioid peptides using an (acyloxy)alkoxy linker
  135. A Ca2+binding cyclic peptide derived from the ?-subunit of LFA-1: inhibitor of ICAM-1 /LFA-1-mediated T-cell adhesion
  136. Molecular Structure of the Apical Junction Complex and Its Contribution to the Paracellular Barrier
  137. Separation and Analysis of Peptides and Proteins
  138. Modulation of Melphalan Resistance in Glioma Cells with a Peripheral Benzodiazepine Receptor Ligand−Melphalan Conjugate
  139. Prodrug strategies to enhance the intestinal absorption of peptides
  140. Synthesis of a Novel Esterase-Sensitive Cyclic Prodrug of a Hexapeptide Using an (Acyloxy)alkoxy Promoiety
  141. Synthesis of a Novel Esterase-Sensitive Cyclic Prodrug System for Peptides That Utilizes a “Trimethyl Lock”-Facilitated Lactonization Reaction
  142. Modulation of the Cellular Junction Protein E-Cadherin in Bovine Brain Microvessel Endothelial Cells by Cadherin Peptides
  143. Modulation of cellular adhesion in bovine brain microvessel endothelial cells by a decapeptide
  144. Derivatives of Melphalan Designed to Enhance Drug Accumulation in Cancer Cells
  145. Novel esterase-sensitive cyclic prodrugs of a model hexapeptide having enhanced membrane permeability and enzymatic stability
  146. Solution Structure of a Cyclic RGD Peptide That Inhibits Platelet Aggregation
  147. Structural requirements for intestinal absorption of peptide drugs
  148. Secondary Structure of the HAV Peptide Which Regulates Cadherin-Cadherin Interaction
  149. Separation and Analysis of Peptides and Proteins
  150. E-Cadherin Peptide Sequence Recognition by Anti-E-Cadherin Antibody
  151. Conformational study of cyclo[Gln-Trp-Phe-Gly-Leu-Met] as NK-2 antagonist by NMR and molecular dynamics
  152. Immobilized peptide arrays: A new technology for the characterization of protease function
  153. Conformational study of cyclo(1,5)-Ac-Pen-Arg-Gly-Asp-Cys-NH2 in water by NMR and molecular dynamics
  154. Delocalized Carbanions in Synthesis
  155. Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings
  156. A new rearrangement of alkoxybenzyl anions
  157. The role of boron trifluoride etherate in reactions of lower order (Gilman) organocuprates
  158. Modeling of the homoeo domain suggests similar structure to repressors
  159. Effects of boron trifluoride etherate on higher order organocuprate reactions: substrate activation or cuprate modification?
  160. Sesquiterpenoid glycosides and an acetogenin glucoside from Lessingia glandulifera
  161. Kolavane diterpenoids of Vanclevea stylosa
  162. Grindelane diterpenoids from Isocoma tenuisecta
  163. Unexpected affects of Me3Si-X on reactions of higher order cyanocuprates
  164. Preparation and reactions of trianions from the dimethylphenols
  165. Five grindelane diterpenoids from Grindelia acutifolia
  166. Havardic acids A-F and havardiol, labdane diterpenoids from Grindelia havardii
  167. A new diterpenoid from Ericameria laricifolia
  168. A New Heterocyclic System from Salol and Phenylacetic Acid
  169. Preparation and reactions of dianions from cresols
  170. Labdane diterpenoids from Grindelia discoidea (asteraceae)
  171. 9,10-Anthracenedicarbaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] acetic acid hydrochloric acid trihydrate salt (bisantrene)
  172. Cardenolides and a lignan from asclepias subulata
  173. Diterpenoids and flavonoids from Grindelia discoidea
  174. Utilization of cell-adhesion peptides to improve drug delivery
  175. Cells activation modulates binding of an LFA-1 peptide to the T-cell adhesion receptors
  176. Synthesis of an Esterase-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability Using an Acyloxyalkoxy Promoiety
  177. Synthesis of an Esterase-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability Using a 3-(2'-Hydroxy-4',6'-Dimethylphenyl)-3,3-Dimethyl Propionic Acid Promoiety
  178. Inhibition of E-cadherin-mediated cell-cell adhesion by cadherin peptides